DOP2010000336A - Uso de una molecula radiomarcada que se une especificamente a la ed-b de la fibronectina en un metodo para el linfoma de hodgkin - Google Patents

Uso de una molecula radiomarcada que se une especificamente a la ed-b de la fibronectina en un metodo para el linfoma de hodgkin

Info

Publication number
DOP2010000336A
DOP2010000336A DO2010000336A DO2010000336A DOP2010000336A DO P2010000336 A DOP2010000336 A DO P2010000336A DO 2010000336 A DO2010000336 A DO 2010000336A DO 2010000336 A DO2010000336 A DO 2010000336A DO P2010000336 A DOP2010000336 A DO P2010000336A
Authority
DO
Dominican Republic
Prior art keywords
lymphoma
hodgkin
hodgkin lymphoma
radiomarced
fibronectine
Prior art date
Application number
DO2010000336A
Other languages
English (en)
Inventor
Hans Dietrich Menssen
Jorg Pinkert
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of DOP2010000336A publication Critical patent/DOP2010000336A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de una molécula radiomarcada que se une específicamente al ED-B de la fibronectina en un método de tratamiento de pacientes con linfoma de Hodgkin, en particular linfoma de Hodgkin primario refractario o linfoma cie Hodgkin recurrente después de una quimioterapia, y cle pacientes con linfoma de Hodgkin programados para recibir una terapia de modalidad combinada primaria.
DO2010000336A 2008-05-08 2010-11-08 Uso de una molecula radiomarcada que se une especificamente a la ed-b de la fibronectina en un metodo para el linfoma de hodgkin DOP2010000336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5150008P 2008-05-08 2008-05-08
EP08075485A EP2116555A1 (en) 2008-05-08 2008-05-08 Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma

Publications (1)

Publication Number Publication Date
DOP2010000336A true DOP2010000336A (es) 2010-12-15

Family

ID=39760894

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000336A DOP2010000336A (es) 2008-05-08 2010-11-08 Uso de una molecula radiomarcada que se une especificamente a la ed-b de la fibronectina en un metodo para el linfoma de hodgkin

Country Status (15)

Country Link
US (1) US20110123444A1 (es)
EP (2) EP2116555A1 (es)
JP (1) JP2011519883A (es)
KR (1) KR20110004867A (es)
CN (1) CN102015768A (es)
AU (1) AU2009243715A1 (es)
BR (1) BRPI0912200A2 (es)
CA (1) CA2723323A1 (es)
DO (1) DOP2010000336A (es)
EA (1) EA201001731A1 (es)
IL (1) IL208615A0 (es)
MA (1) MA32289B1 (es)
MX (1) MX2010012215A (es)
SV (1) SV2010003728A (es)
WO (1) WO2009135627A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
CN108291915B (zh) * 2015-11-16 2021-01-05 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU664030B2 (en) 1991-02-27 1995-11-02 Micromet Ag Serine-rich peptide linkers
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
WO2001062298A2 (en) 2000-02-24 2001-08-30 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
AU2003210149B2 (en) 2002-01-03 2008-10-09 Bayer Schering Pharma Aktiengesellschaft Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours
US8491906B2 (en) 2002-03-11 2013-07-23 Philogen S.P.A. Selective targeting of tumor vasculature using antibody molecules
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途

Also Published As

Publication number Publication date
CN102015768A (zh) 2011-04-13
EP2116555A1 (en) 2009-11-11
US20110123444A1 (en) 2011-05-26
EA201001731A1 (ru) 2011-06-30
AU2009243715A1 (en) 2009-11-12
BRPI0912200A2 (pt) 2016-07-26
WO2009135627A1 (en) 2009-11-12
SV2010003728A (es) 2011-03-15
KR20110004867A (ko) 2011-01-14
MA32289B1 (fr) 2011-05-02
MX2010012215A (es) 2010-12-06
CA2723323A1 (en) 2009-11-12
EP2276779A1 (en) 2011-01-26
JP2011519883A (ja) 2011-07-14
IL208615A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
ECSP088618A (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4
MY159553A (en) Detection and treatment of pancreatic, ovarian and other cancers
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
AU324651S (en) Bottle
EA201171367A1 (ru) Винилиндазолильные соединения
EA201001372A1 (ru) Формы рифаксимина и их применение
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
GB2464245A (en) Managing risk associated with various transactions
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
BR112012016742A2 (pt) metodos para tratamento de cancer pancreatico
CR20110553A (es) Terapia complementaria contra el cáncer
HN2009003038A (es) Anticuerpos contra la il-25
BRPI0906404B8 (pt) construção de fusão com domínio lítico, seus usos, composição farmacêutica, bem como processo para reduzir ou inibir seletivamente a proliferação de uma célula que expressa um receptor, ligante ou antígeno
TW200744568A (en) Epinephrine dosing regimens
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
CL2009001082A1 (es) Procedimiento para tratar artritis indiferenciada que comprende administrar una molecula de ctla4 que se une a cd80 y/o cd86.
MX2011006725A (es) Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
AU316948S (en) Toothbrush
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.